FierceBiotech

Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment

The randomized, controlled, 100-patient Phase 2 study is comparing the safety and efficacy of intravenous picoplatin given once every four weeks in combination with 5-fluorouracil and leucovorin in ...
FierceBiotech

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial for Metastatic Colorectal Cancer

SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, ...
ascopubs.org

Randomized phase II study of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a neuropathy-sparing alternative to modified FOLFOX-6 as first-line therapy ...

Evaluation of the effect of intravenous calcium and magnesium (CaMg) on chronic and acute neurotoxicity associated with oxaliplatin: Results from a placebo-controlled phase III trial This is an ASCO ...
Medindia

Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives

- Statistical data support picoplatin as a potential neuropathy-sparing alternative to oxaliplatin - SOUTH SAN FRANCISCO, Calif., Jan. 24 /PRNewswire-FirstCall ...
ascopubs.org

First-line phase Ib and II studies of picoplatin in combination with 5-fluorouracil and leucovorin (FOLPI) as a potential neuropathy-sparing therapy for colorectal cancer (CRC)

This is an ASCO Meeting Abstract from the 2008 ASCO Annual Meeting. This abstract does not include a full text component.
BioWorld

Poniard's Picoplatin Phase II: Target Hit, Analysts Skeptical

Partnering hopes may have dimmed for Poniard Pharmaceuticals Inc. with the unveiling of Phase II results with picoplatin in metastatic colorectal cancer, news that follows the failure of the ...
Medindia

Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer

SOUTH SAN FRANCISCO, Calif. and GENEVA, Oct. 22 Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical companyfocused on oncology, today announced positive incremental data from ...
technologynetworks

Poniard Announces Positive Preliminary Data from Ongoing Phase 2 Trial of Picoplatin

Poniard Pharmaceuticals, Inc. has announced positive preliminary results from its ongoing randomized Phase 2 clinical trial in patients with metastatic colorectal cancer (CRC) and updated results from ...
Finanznachrichten

Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer

Preliminary data suggest that FOLPI and FOLFOX may have similar anti-tumor activity in metastatic CRC. Preliminary data representing 61 patients will be presented. Of 11 evaluable patients in the ...
Finanznachrichten

Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives / Statistical data support picoplatin ...

-- No hypersensitivity, cardiac or nephrotoxicity was observed with FOLPI or FOLFOX. -- FOLPI had more frequent and severe, but manageable, thrombocytopenia and neutropenia; complications were rare, ...